Thrombosis Archives - PharmaLive

Clotting Risks Cause FDA to Restrict Use of J&J Vaccine

Adults 18 & Older, CDC, Emergency Use Authorization (EUA), FDA, Janssen, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, Novel Coronavirus, Therapeutics, Thrombosis with thrombocytopenia syndrome (TTS)

The Janssen COVID-19 vaccine is now limited to certain individuals ages 18 and up after the U.S. Food and Drug Administration downgraded its emergency use authorization.

May 6, 2022/by Andrew Humphreys

Merck Sets $10 Billion Target for Cardiovascular Pipeline by Mid-2030

Acquisitions, Atherosclerosis, Business, Cardiovascular, Merck, Product Pipeline, Pulmonary Arterial Hypertension, Pulmonology, R&D, Therapeutics, Thrombosis

Merck’s cardiopulmonary pipeline is poised to deliver eight potential approvals over the next eight years, bolstering the company’s pipeline and revenue.

April 5, 2022/by BioSpace

AstraZeneca finds small clot risk after 1st COVID shot, less after 2nd

AstraZeneca, Blood Clots, COVID-19 shots, COVID-19 Studies, COVID-19 Vaccinations, European Medicines Agency (EMA), Oxford University, Side Effects, The Lancet, Thrombosis with thrombocytopenia syndrome (TTS)

AstraZeneca’s Covid-19 vaccine carries a small extra risk of rare blood clots with low platelets after the first dose and no extra risk after the second, a study led and funded by the drugmaker showed on July 28, after worries over side effects.

July 28, 2021/by Andrew Humphreys

Anthos Developing Hemostasis-Sparing Anticoagulant to Reduce Bleeding Hazard

Anticoagulants, Biotech, Blood Clots, Blood Thinner, Blood Vessels, Business, Cardiovascular Disease, Clinical Trials, Heart Attacks, Heart Disease, R&D, Start-Ups, Strokes, Thrombosis

Anthos Therapeutics is developing next-generation anticoagulants that do not have the bleeding risks that current blood thinners have.

September 10, 2020/by BioSpace